Ranbaxy Launches Anti-Allergic Nasal Spray (India)
This article was originally published in PharmAsia News
Executive Summary
Indian pharmaceutical major Ranbaxy Laboratories has launched a new nasal spray in India. The spray, called Osonase (ciclesonide), is designed to treat both seasonal and perennial allergies. Osonase is approved for use in both adults and teenagers. The latest edition joins Ranbaxy's lineup of allergy medications. The company has also recently developed a number of delivery mechanisms for asthma treatments, including dry-powder inhalers, and inhalers that use hydro fluoro alkane as an environmentally conscious propellant. (Click here for more
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.